Galderma debuts skin regenerative brand Alastin in China
Key takeaways
- Galderma is debuting its Alestin brand in China with four medical skin care products.
- China’s medical aesthetics market is expected to increase by 15% in the coming decade.
- The launch comes as Alestin is celebrating its 10th anniversary in business.
Galderma has launched four products under its Alastin brand in China. The move marks the medical skin care company’s debut in the “fast-growing global market for aesthetic skin care,” according to Galderma.
The products from Alastin offer “full spectrum care” targeting consumers undergoing aesthetic procedures. They aim to support the skin’s natural regeneration and improve overall skin care results.
The care includes pre-treatment preparation, post-treatment recovery, and at-home maintenance.
“With Alastin by Galderma, we have a comprehensive perioperative solution to enhance skin recovery around aesthetic treatment and maintenance programs that bring together Galderma’s leading expertise in dermatological skin care and injectable aesthetics,” says Alan D. Widgerow, chief scientific officer and head of skin science center for Innovations at Alastin, Galderma.
“As the Asia-Pacific region’s beauty and aesthetics market continues to grow, we’re proud to bring Alastin to patients in China who are seeking advanced solutions to support them in their aesthetic journeys.”
The launch in China is the first to include Alastin’s new packaging featuring a “re-energized, premium look and feel.” The brand hopes the release builds on its growth in key markets including the US, Canada, and the UK.
The launch comes as Alastin celebrates its 10th anniversary. Galderma says the brand is backed by science and has been included in 50 global dermatological publications and has 22 patents.
Tapping into China
The four products reflect the company’s holistic approach to aesthetic care.
China’s medical aesthetics market is expected to increase by 15% in the coming decade and is currently experiencing “remarkable growth,” according to Galderma.
The company attributes the growth to medical aesthetics going mainstream rather than remaining niche. This increases the demand and consumers’ willingness to invest in such advanced technologies and products.
Galderma acquired Alastin in 2021, and therefore also acquired its patented TriHex Technology — a proprietary blend of peptides and active botanicals to support rejuvenated skin appearance.
Combining the TriHex technology with other active ingredients may soothe, restore, and calm sensitive and post-treatment skin.
The products launched in China are also powered by TriHex Technology, enhancing skin recovery and regeneration.
Last year, L’Oréal acquired a 10% stake in Galderma to expand its dermatology category. The companies signed a memorandum of understanding to collaborate on R&D through a scientific partnership.
